G2-TR_iDoseTR
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 863 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 863 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | Glaukos Corporation | $1.2M | 1 |
| Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% | Glaukos Corporation | $139,021 | 3 |
| Prospective, Non-Randomized, Open-Label, Multi-Center, Single Arm Study of Exchange of Travoprost Intraocular Implant | Glaukos Corporation | $6,776 | 0 |
Manufacturing Companies
- Glaukos Corporation $1.4M
Product Information
- Type Device
- Total Payments $1.4M
- Total Doctors 3
- Transactions 863
About G2-TR_iDoseTR
G2-TR_iDoseTR is a device associated with $1.4M in payments to 3 healthcare providers, recorded across 863 transactions in the CMS Open Payments database. The primary manufacturer is Glaukos Corporation.
Payment data is available from 2024 to 2024. In 2024, $1.4M was paid across 863 transactions to 3 doctors.
The most common payment nature for G2-TR_iDoseTR is "Unspecified" ($1.4M, 100.0% of total).
G2-TR_iDoseTR is associated with 3 research studies, including "Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension" ($1.2M).